N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development.
The potential involvement of N-acetyltransferase 1 (NAT1) genetic polymorphisms in prostate cancer (PCa) patients was analyzed in 101 patients with PCa and 97 controls with no incidental malignancy. Identification of NAT1*10, the variant allele associated with the rapid acetylator phenotype was by allele-specific polymerase chain reaction (PCR). When the NAT1*10 heterozygote and other genotypes without NAT1*10 allele were considered as low risk genotypes, NAT1*10/NAT1*10 had a significantly higher risk of PCa (OR = 2.4, 95% CI; 1.0-5.6). If our preliminary results can be confirmed in a larger population, it may be a useful marker for PCa risk.
Fukutome
K
K
Department of Pathology, Mie University School of Medicine, Tsu, Japan. tome@doc.medic.mie-u.ac.jp
Watanabe
M
M
Shiraishi
T
T
Murata
M
M
Uemura
H
H
Kubota
Y
Y
Kawamura
J
J
Ito
H
H
Yatani
R
R
D000483:Alleles; D001191:Arylamine N-Acetyltransferase / Q000235:genetics*; D014408:Biomarkers, Tumor / Q000235:genetics*; D016022:Case-Control Studies; D005838:Genotype; D006579:Heterozygote; D006801:Humans; D007527:Isoenzymes / Q000235:genetics*; D008297:Male; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000235:genetics*; D012306:Risk; D012307:Risk Factors
D014408:Biomarkers, Tumor; D007527:Isoenzymes; D001191:Arylamine N-Acetyltransferase; C089384:N-acetyltransferase 1